Compare IHRT & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | PACB |
|---|---|---|
| Founded | 1974 | 2000 |
| Country | United States | United States |
| Employees | 9550 | N/A |
| Industry | Broadcasting | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.7M | 419.8M |
| IPO Year | N/A | 2010 |
| Metric | IHRT | PACB |
|---|---|---|
| Price | $3.40 | $1.42 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $4.25 | $2.13 |
| AVG Volume (30 Days) | 629.1K | ★ 5.4M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $9.96 | $11.32 |
| Revenue Next Year | N/A | $12.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $0.95 | $0.85 |
| 52 Week High | $5.44 | $2.73 |
| Indicator | IHRT | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 47.37 |
| Support Level | $2.53 | $1.36 |
| Resistance Level | $3.51 | $1.51 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 87.73 | 48.61 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.